Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 369 results:
Συντάκτης Τίτλος [ Τύπος] Έτος Φίλτρα: Συντάκτης is Polyzos, Stergios A [Clear All Filters]
A novel noninvasive index for nonalcoholic steatohepatitis: a pilot study..
Biomarkers. 18(7), 607-13.
(2013). Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics..
Metabolism. 92, 82-97.
(2019). Obesity and the nervous system: more questions..
Lancet Neurol. 16(10), 772-773.
(2017). Obesity: seize the day, fight the fat..
Metabolism. 92, 1-5.
(2019). Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns..
Metabolism. 104, 154144.
(2020). Of mice and men: Why progress in the pharmacological management of obesity is slower than anticipated and what could be done about it?.
Metabolism. 96, vi-xi.
(2019). Off-label uses of denosumab in metabolic bone diseases..
Bone. 129, 115048.
(2019).
(2023). Outliers of bone metabolic diseases..
Metabolism. 80, 1-4.
(2018). Paget's disease of bone: emphasis on treatment with zoledronic acid..
Expert Rev Endocrinol Metab. 4(5), 423-434.
(2009). Papillary thyroid microcarcinoma presenting as lymph node metastasis--a diagnostic challenge: case report and systematic review of literature..
Hormones (Athens). 11(4), 419-27.
(2012). Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis..
Clin Endocrinol (Oxf). 79(4), 499-503.
(2013).
(2024). Peptide Polyagonists for the Treatment of Nonalcoholic Fatty Liver Disease..
Curr Pharm Des. 29(41), 3263-3265.
(2023). Periostin and sclerostin levels in juvenile Paget's disease..
Clin Cases Miner Bone Metab. 14(2), 269-271.
(2017). Periostin on the road to nonalcoholic fatty liver disease..
Endocrine. 51(1), 4-6.
(2016). A perspective on risk factors for esophageal adenocarcinoma: emphasis on Helicobacter pylori infection..
Ann N Y Acad Sci. 1452(1), 12-17.
(2019). Pharmacotherapy of obesity: Available medications and drugs under investigation..
Metabolism. 92, 170-192.
(2019). Pharmacotherapy of type 2 diabetes: An update..
Metabolism. 78, 13-42.
(2018). Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations..
Maturitas. 147, 19-25.
(2021). The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature..
J Clin Gastroenterol. 45(1), 50-4.
(2011). Potential Impact of Active Helicobacter pylori Infection with or without Concomitant Metabolic Syndrome on Colorectal Cancer Invasion and Mortality..
Isr Med Assoc J. 20(11), 725-726.
(2018). Potential impact of Helicobacter pylori and metabolic syndrome-related non-alcoholic fatty liver disease on cardio-cerebrovascular disease..
Metabolism. 135, 155276.
(2022).
(2017).
(2023).